Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120)

被引：0
|
作者：
Zukin, M. [1 ]
Gelatti, A. C. Z. [2 ]
Gondim, V. [3 ]
Shimada, A. K. [4 ]
Magalhaes, E. [5 ]
Mathias, C. [6 ]
Barra, W. F. [7 ]
William Junior, W. N. [8 ]
Padoan, M. [3 ]
Bittencourt, Y. [4 ]
Yamamura, R. [8 ]
Gossling, G. [9 ]
Rebelatto, T. F. [9 ]
de Jesus, R. G. [9 ]
Silva, C. E. B. [10 ]
机构：
[1] Oncol & Inst, Sao Paulo, Brazil
[2] CPO Porto Alegre, Porto Alegre, RS, Brazil
[3] Inst Amer, Rio De Janeiro, Brazil
[4] Hosp Sirio Libanes, Sao Paulo, SP, Brazil
[5] Inst Mario Penna, Belo Horizonte, MG, Brazil
[6] Oncoclin BA & Hosp Santa Izabel, Salvador, BA, Brazil
[7] Univ Fed Nucl Pesquisa Oncol, Belem, Para, Brazil
[8] BP A Beneficencia Portuguesa Sao Paulo, Sao Paulo, SP, Brazil
[9] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, RS, Brazil
[10] Hosp Canc Barretos, Barretos, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-Small Cell Lung Cancer; Durvalumab; Brazil;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-30
引用
收藏
页码：S582 / S582
页数：1
相关论文
共 50 条
  • [1] Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
    Zukin, Mauro
    Gondim, Victor
    Shimada, Andrea Kazumi
    Lima, Ellias Magalhaes e Abreu
    Mathias, Clarissa
    Barra, Williams Fernandes
    William Jr, William Nassib
    Padoan, Monica
    Bittencourt, Yuri
    Yamamura, Rosely
    Silva, Carlos Eduardo Baston
    Rossato, Leticia de Jesus
    Monteiro, Caio de Almeida
    Jesus, Rafaela Gomes de
    Gossling, Gustavo
    Gelatti, Ana Caroline Zimmer
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2024, 50 (06)
  • [2] Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
    Mehra, Ranee
    Yong, Candice
    Seal, Brian
    van Keep, Marjolijn
    Raad, Angie
    Zhang, Yiduo
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (02): : 153 - +
  • [3] Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study
    Zhao, Binghao
    Li, Huanzhang
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : e38 - e39
  • [4] Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
    Vansteenkiste, Johan F.
    Naidoo, Jarushka
    Faivre-Finn, Corinne
    Ozguroglu, Mustafa
    Villegas, Augusto
    Daniel, Davey
    Murakami, Shuji
    Hui, Rina
    Lee, Ki Hyeong
    Cho, Byoung Chul
    Kubota, Kaoru
    Broadhurst, Helen
    Wadsworth, Catherine
    Newton, Michael
    Thiyagarajah, Piruntha
    Antonia, Scott J.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (03):
  • [5] DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy
    Filippi, Andrea R.
    Dziadziuszko, Rafal
    Garcia Campelo, Maria Rosario
    Paoli, Jean-Baptiste
    Sawyer, William
    Diaz Perez, Ignacio Esteban
    FUTURE ONCOLOGY, 2021, 17 (34) : 4657 - 4663
  • [6] Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
    Cortiula, Francesco
    De Ruysscher, Dirk
    Steens, Michelle
    Wijsman, Robin
    van der Wekken, Anthonie
    Alberti, Martina
    Hendriks, Lizza E. L.
    EUROPEAN JOURNAL OF CANCER, 2023, 184 : 172 - 178
  • [7] Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
    Adrien Holzgreve
    Julian Taugner
    Lukas Käsmann
    Philipp Müller
    Amanda Tufman
    Niels Reinmuth
    Minglun Li
    Michael Winkelmann
    Lena M. Unterrainer
    Alexander E. Nieto
    Peter Bartenstein
    Wolfgang G. Kunz
    Jens Ricke
    Claus Belka
    Chukwuka Eze
    Marcus Unterrainer
    Farkhad Manapov
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2466 - 2476
  • [8] Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
    Holzgreve, Adrien
    Taugner, Julian
    Kaesmann, Lukas
    Mueller, Philipp
    Tufman, Amanda
    Reinmuth, Niels
    Li, Minglun
    Winkelmann, Michael
    Unterrainer, Lena M.
    Nieto, Alexander E.
    Bartenstein, Peter
    Kunz, Wolfgang G.
    Ricke, Jens
    Belka, Claus
    Eze, Chukwuka
    Unterrainer, Marcus
    Manapov, Farkhad
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (08) : 2466 - 2476
  • [9] The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
    Kim, Y.
    Choi, Y-K
    Kwak, Y-K
    Lee, Y-H
    Kim, S-H
    Sung, S-Y
    Son, S-H
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S281 - S281
  • [10] Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
    Girard, Nicolas
    Bar, Jair
    Garrido, Pilar
    Garassino, Marina C.
    McDonald, Fiona
    Mornex, Francoise
    Filippi, Andrea R.
    Smit, Hans J. M.
    Peters, Solange
    Field, John K.
    Christoph, Daniel C.
    Sibille, Anne
    Fietkau, Rainer
    Haakensen, Vilde D.
    Chouaid, Christos
    Markman, Ben
    Hiltermann, T. Jeroen N.
    Taus, Alvaro
    Sawyer, William
    Allen, Allison
    Chander, Pratibha
    Licour, Muriel
    Solomon, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) : 181 - 193
12345